387,545 Shares in Harrow, Inc. $HROW Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC bought a new position in Harrow, Inc. (NASDAQ:HROW) in the second quarter, HoldingsChannel reports. The fund bought 387,545 shares of the company’s stock, valued at approximately $16,459,000.

Other hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its stake in Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after acquiring an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Harrow by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after acquiring an additional 790 shares during the period. Strs Ohio bought a new stake in shares of Harrow in the first quarter worth approximately $149,000. Legal & General Group Plc raised its holdings in shares of Harrow by 12.4% during the second quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock valued at $939,000 after purchasing an additional 3,384 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Harrow by 9.3% during the second quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock valued at $1,434,000 after purchasing an additional 3,994 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Stock Down 1.4%

Shares of HROW stock opened at $39.47 on Tuesday. The company has a current ratio of 2.24, a quick ratio of 2.08 and a debt-to-equity ratio of 19.70. Harrow, Inc. has a 12 month low of $28.54 and a 12 month high of $54.85. The stock has a market cap of $1.48 billion, a P/E ratio of -39.47 and a beta of 0.28. The company has a 50 day simple moving average of $41.07 and a two-hundred day simple moving average of $39.83.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The business had revenue of $70.66 million for the quarter, compared to analysts’ expectations of $70.35 million. Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%. On average, research analysts expect that Harrow, Inc. will post 0.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HROW. Cantor Fitzgerald dropped their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Finally, BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Tuesday, August 11th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $69.43.

Insider Transactions at Harrow

In related news, insider Amir Shojaei sold 11,250 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider directly owned 11,250 shares in the company, valued at approximately $450,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 12.80% of the company’s stock.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.